Serum oncostatin M in multiple myeloma: impact on disease severity and prognosis |
| |
Authors: | Koskela K Pelliniemi T T Rajamäki A Pulkki K Remes K |
| |
Institution: | Department of Medicine, Turku University Central Hospital, Finland. |
| |
Abstract: | Since high levels of serum IL-6 predict a poor prognosis of patients with multiple myeloma (MM), we investigated if a related cytokine, oncostatin M (OSM), correlates with clinical or biochemical findings or has prognostic significance in patients with MM. Among 82 newly diagnosed MM patients, OSM was detected in the sera in 45 (55%). Serum OSM had a borderline statistical correlation with serum IL-6 (r = 0.198, p = 0.074) and C-reactive protein (r = 0.199, p = 0.074) concentrations. However, OSM did not have prognostic significance alone or in combination with other factors. The median survival of patients with detectable serum OSM concentration was 41 months (range 2-124 months) and of OSM negative patients 35 months (1-75 months). Serum OSM concentration was not associated with clinical factors or severity of bone disease at diagnosis. We conclude that serum OSM concentration is not a prognostic factor in MM patients. |
| |
Keywords: | oncostatin M cytokine multiple myeloma prognostic factor |
本文献已被 PubMed 等数据库收录! |
|